La possibilité d'une thérapie génique antitumorale amplifiée par l'induction de la communication fonctionnelle intercellulaire

Medecine/Sciences

Volumn 12, Issue 12, 1996, Pages 1435-1438

  Mesnil, Marc ^a   Yamasaki, Hiroshi ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 5744224334     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.4267/10608/692     Document Type: Article

References (27)

1. Kaldor JM, Day NE, Pettersson F, Clarke EA, Pedersen D, et al. Leukemia following chemotherapy for ovarian cancer. N Engl J Med 1990; 322: 1-6.
2. Kahn A. Thérapie génique: le temps d'un premier bilan. médecine/sciences 1996; 12: 9-12.
3. Mannoni P. La thérapie génique du cancer: désir mythique ou réalité therapeutique de demain? médecine/sciences 1996; 12: 68-72.
4. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992; 256: 1550-2.
5. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, Abraham GN. The «bystander effect»: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274-83.
6. Meda P. Connexines, canaux jonctionnels et communications cellulaires. médecine/sciences 1996; 12: 909-20.
7. Goldberg G, Bertram JS. Correspondance re: Z. Ram et al. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res 1994; 54: 3947-8.
8. Pitts JD. Cancer gene therapy: a bystander effect using the gap junctional pathway. Molecular Carcinogen 1994; 11: 127-30.
9. Bi WL, Parysek LM, Warnick R, Stambrook PJ. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum Gene Ther 1993; 4: 725-31.
10. Fick J, Barker II FG, Dazin P, Westphale EM, Beyer EC, Israel MA. The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. Proc Natl Acad Sci USA 1995; 92: 11071-5.
11. Yamasaki H, Katoh F. Novel method for selective killing of transformed rodent cells through intercellular communication, with possible therapeutic applications. Cancer Res 1988; 48: 3203-7.
12. Yamasaki H, Hollstein M, Mesnil M, Martel N, Aguelon AM. Selective lack of intercellular communication between transformed and nontransformed cells as a common property of chemical and oncogene transformation of BALB/c 3T3 cells. Cancer Res 1987; 47: 5656-64.
13. Mesnil M, Piccoli C, Tiraby G, Willecke K, Yamasaki H. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci USA 1996; 93: 1831-5.
14. Elfgang C, Eckert R, Lichtenberg-Fraté H, Butterweck A, Traub O, Klein RA, Hülser DF, Willecke K. Specific permeability and selective formation of gap junction channels in connexin-transfected HeLa cells. J Cell Biol 1995; 129: 805-17.
15. Elshami AA, Saavedra A, Zhang H, Kucharczuk JC, Spray DC, Fishman GI, Amin KM, Kaiser LR, Albelda SM, Gap junctions play a role in the «bystander effect» of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Therapy 1996; 3: 85-92.
16. Samejima Y, Meruelo D. «Bystander killing» induces apoptosis and is inhibited by forskolin. Gene Therapy 1995; 2: 50-8.
17. Vile RG, Nelson JA, Castleden S, Chong H, Hart IR. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res 1994; 54: 6228-34.
18. Ram Z, Culver KW, Walbridge S, Blaese M, Oldfield EH. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res 1993; 53: 83-8.
19. Mesnil M, Yamasaki H. Le cancer, un problème de communication? La Recherche 1994; 261: 76-8.
20. Mesnil M, Oyamada M, Fitzgerald DJ, Jongen WMF, Krutovskikh V, Yamasaki H. Gap junctional communication alterations at various regulatory levels of connexin expression and function during animal and human carcinogenesis. Prog Cell Res 1993; 3: 311-6.
21. Zhang LX, Cooney RV, Bertram JS. Carotenoids up-regulate connexin 43 gene expression independently of their pro-vitamin A or antioxidant properties. Cancer Res 1992;52:5707-12.
22. Mehta PP, Yamamoto M, Rose B. Transcription of the gene for the gap junctional channel protein connexin 43 and expression of functional cell-to-cell channels are regulated by cAMP. Mol Biol Cell 1992; 3: 839-50.
23. Eghbali B, Kessler JA, Reid LM, Roy C, Spray DC. Involvement of gap junctions in tumorigenesis: transfection of tumor cells with connexin 32 cDNA retards growth in vivo. Proc Natl Acad Sci USA 1991; 88: 10701-5.
24. Zhu D, Caveney S, Kidder GM, Naus CCG. Transfection of C6 glioma cells with connexin 43 cDNA: analysis of expression, intercellular coupling, and cell proliferation, Proc Natl Acad Sci USA 1991; 88: 1883-7.
25. Rose B, Mehta PP, Loewenstein WR. Gap-junction protein gene suppresses turnorigenicity. Carcinogenesis 1993; 14: 1073-5.
26. Naus CCG, Elisevich K, Zhu D, Belliveau DJ, Del Maestro RF. In vivo growth of C6 glioma cells transfected with connexin 43 cDNA. Cancer Res 1992; 52: 4208-13.
27. Mesnil M, Krutosvkikh V, Piccoli C, Elfgang C, Traub O, Willecke K, Yamasaki H. Negative growth control of HeLa cells by connexin genes: connexin species specificity. Cancer Res 1995; 55: 629-39.